In-house AIDD modules for target discovery and molecule design
AI drug discovery Deployment
Disclosed: Verified:
At its 2025 R&D day, Hengrui said AI-driven drug R&D has become an important innovation engine. It said it is relying on an AI target-discovery platform, an AI large-molecule design platform, an AI small-molecule generation and optimization platform, a specialized drug-research large model and AI drug-research agents to improve the efficiency of target discovery, molecule design and developability optimization.
Source
Company Archive pending